Evidence map›Paper›PMID 38501900›Full record

ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2024

Structural Stabilization of Clinically Oriented Oligomeric Proteins During their Transit through Synthetic Secretory Amyloids.

Julieta M Sánchez, Hèctor López-Laguna, Eloi Parladé, Angela Di Somma, Andrea L Livieri, Patricia Álamo, Ramón Mangues, Ugutz Unzueta, Antonio Villaverde, Esther Vázquez

Open access · goldAbstract read
In one paragraph

Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
2.3field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 3 countries.

Julieta M SánchezInstitut de Biotecnologia i de Biomedicina, Universitat Autònoma de Barcelona, Plaça Cívica s/n, Bellaterra, Barcelona, 08193, Spain.
Hèctor López-LagunaInstitut de Biotecnologia i de Biomedicina, Universitat Autònoma de Barcelona, Plaça Cívica s/n, Bellaterra, Barcelona, 08193, Spain.
Eloi ParladéInstitut de Biotecnologia i de Biomedicina, Universitat Autònoma de Barcelona, Plaça Cívica s/n, Bellaterra, Barcelona, 08193, Spain.
Angela Di SommaInstitut de Biotecnologia i de Biomedicina, Universitat Autònoma de Barcelona, Plaça Cívica s/n, Bellaterra, Barcelona, 08193, Spain.
Andrea L LivieriInstitut de Biotecnologia i de Biomedicina, Universitat Autònoma de Barcelona, Plaça Cívica s/n, Bellaterra, Barcelona, 08193, Spain.
Patricia ÁlamoInstitut de Recerca Sant Pau (IR SANT PAU), Sant Quintí 77-79, Barcelona, 08041, Spain.
Ramón ManguesCIBER de Bioingeniería, Biomateriales y Nanomedicina (CIBER-BBN), Barcelona, 08024, Spain.
Ugutz UnzuetaDepartament de Genètica i de Microbiologia, Universitat Autònoma de Barcelona, Plaça Cívica s/n, Bellaterra, Barcelona, 08193, Spain.
Antonio VillaverdeInstitut de Biotecnologia i de Biomedicina, Universitat Autònoma de Barcelona, Plaça Cívica s/n, Bellaterra, Barcelona, 08193, Spain.ORCID 0000-0002-2615-4521
Esther VázquezInstitut de Biotecnologia i de Biomedicina, Universitat Autònoma de Barcelona, Plaça Cívica s/n, Bellaterra, Barcelona, 08193, Spain.
Universitat Autònoma de Barcelona · ESHospital de Sant Pau · ES

Funding

AGAUR 2019FI_B00352AGAUR 2020PANDE00003AGAUR 2021SGR-00092Agencia Estatal de Investigación PDC2022-133858-I00Agencia Estatal de Investigación PID2019-105416RB-I00/AEI/10.13039/501100011033Agencia Estatal de Investigación PID2020-116174RB-I00Agencia Estatal de Investigación PID2022-136845OB-I00Centro de Investigación Biomédica en Red en Bioingeniería, Biomateriales y Nanomedicina CB06/01/0014Centro de Investigación Biomédica en Red en Bioingeniería, Biomateriales y Nanomedicina NANOREMOTECentro de Investigación Biomédica en Red en Bioingeniería, Biomateriales y Nanomedicina NANOSCAPECentro de Investigación Biomédica en Red en Bioingeniería, Biomateriales y Nanomedicina VENOM4CANCERInstituto de Salud Carlos III CP19/00028Instituto de Salud Carlos III PI20/00400Instituto de Salud Carlos III PI21/00150Instituto de Salud Carlos III PI23/00318Ministerio de Universidades Maria_Zambrano_677904
6 · The paper itself

Abstract

Developing time-sustained drug delivery systems is a main goal in innovative medicines. Inspired by the architecture of secretory granules from the mammalian endocrine system it has generated non-toxic microscale amyloid materials through the coordination between divalent metals and poly-histidine stretches. Like their natural counterparts that keep the functionalities of the assembled protein, those synthetic structures release biologically active proteins during a slow self-disintegration process occurring in vitro and upon in vivo administration. Being these granules formed by a single pure protein species and therefore, chemically homogenous, they act as highly promising time-sustained drug delivery systems. Despite their enormous clinical potential, the nature of the clustering process and the quality of the released protein have been so far neglected issues. By using diverse polypeptide species and their protein-only oligomeric nanoscale versions as convenient models, a conformational rearrangement and a stabilization of the building blocks during their transit through the secretory granules, being the released material structurally distinguishable from the original source is proved here. This fact indicates a dynamic nature of secretory amyloids that act as conformational arrangers rather than as plain, inert protein-recruiting/protein-releasing granular depots.

Indexed as

AmyloidDrug Delivery SystemsHumansProtein ConformationSecretory VesiclesAmyloidcell‐targetingdrug deliverymicroparticlesnanoparticlesrecombinant proteinssecretory granules

Identifiers

PMID38501900
PMCPMC11151067
OpenAlexW4392953426

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.